Loma Linda University

llu.edu

Total trials

304

Active

57

Phase 3

15

Total enrollment

245,481

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 14 of 14 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Normal Saline4
Gabapentin 600mg1
Aspirin 325Mg Tab, Aspirin 81Mg Tab1
iron sulfate1
Magnesium sulfate1
Toothpaste2
Conventional Toothpaste2
Oral Nifedipine1
Oral Labetalol1
Povidone-Iodine1
Gemcitabine 1000 mg1
nab-paclitaxel1
Lidocaine3
Morphine 0,1 mg/kg1

Next readouts

  • 2026-09
  • 2026-10
  • 2026-12
  • 2026-12
  • 2026-12
  • 2026-12
  • 2027-03
  • 2027-05
  • 2027-06
  • 2027-12

Top conditions

  • Obesity9
  • Inflammation8
  • Autism Spectrum Disorder6
  • Immune Response5
  • Pain5
  • Postoperative Pain4
  • Type 2 Diabetes4
  • Traumatic Brain Injury4

Frequently asked questions about Loma Linda University

How many clinical trials does Loma Linda University have on ClinicalTrials.gov?
Loma Linda University is listed as the lead sponsor on 304 clinical trials in ClinicalTrials.gov, 57 of which are currently active (recruiting, enrolling, or ongoing).
How many of Loma Linda University's trials are in Phase 3?
15 of Loma Linda University's trials are in Phase 3, spread across 14 active drug programs.
What therapeutic areas does Loma Linda University focus on?
Loma Linda University's most-studied conditions on ClinicalTrials.gov are Obesity, Inflammation, Autism Spectrum Disorder, Immune Response, Pain.
When are Loma Linda University's next clinical trial readouts?
Loma Linda University has 10 upcoming primary-completion readouts tracked here; the soonest is “Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer”, expected around 2026-09.